 Patient reported outcomes PRO have become an important endpoint assessed in clinical trials. It is important to understand the relationship between medication and patients symptomatology, quality of life and wellbeing. We predict Duodopa will significantly improve quality of life and emotional wellbeing compared to baseline in patients with advance Parkinson disease APD not well controlled with conventional treatment. 